Dr. Karam joined Ambry Genetics in 2014 as part of Ambry’s first team of scientists dedicated solely to the interpretation of genetic tests’ results. In 2016 he played a key leadership role in the launch of the industry’s first research laboratory dedicated to studying variants of unknown significance, the Ambry Translational Genomics (ATG) Lab. More recently, he was instrumental in the development and clinical implementation of RNA-based genetic testing. He also actively participates in several ClinGen committees dedicated to creating guidelines for the interpretation of genetic testing and is currently the Chair of the CDH1 ClinGen expert panel. Dr Karam obtained his M.D. in 2003, in Brazil, and his Ph.D. in Oncogenetics in 2008, at the University of Porto, Portugal. He did his postdoctoral studies at the University of California, San Diego (UCSD) from 2009 to 2014.